Please ensure Javascript is enabled for purposes of website accessibility Andy Acker, CFA - Janus Henderson Investors - Europe PA Luxembourg
For financial professionals in Luxembourg

Andy Acker, CFA

Portfolio Manager
Andy Acker, CFA | Janus Henderson Investors

Andy Acker is Portfolio Manager of the Healthcare and Biotech strategies at Janus Henderson Investors and leads the firm’s Health Care Sector Research Team, a position he has held since 2007. Andy was an assistant portfolio manager on the healthcare strategy from 2003 to 2007. He joined Janus in 1999 as a research analyst focused on companies in the biotechnology and pharmaceutical industries. Prior to this, he worked as a strategy consultant for the Boston Consulting Group and as a health care analyst for Morgan Stanley Venture Partners.

Andy received his Bachelor of Science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA with honours from Harvard Business School. Andy holds the Chartered Financial Analyst designation and has 28 years of financial industry experience.

Download hi-res headshot

Articles Written

Healthcare stocks shine in a dimming economy
Timely & Topical

Healthcare stocks shine in a dimming economy

The sector’s traditionally defensive qualities and accelerating innovation could stand out amid a potentially slowing economy.

Shaping a Brighter Future: AI’s impact on healthcare
Timely & Topical

Shaping a Brighter Future: AI’s impact on healthcare

Hear how AI and other advances in healthcare are transforming patient outcomes and leading to new investment opportunities.

Will a new candidate create volatility for healthcare stocks?
Timely & Topical

Will a new candidate create volatility for healthcare stocks?

Why we do not expect the last-minute change in the U.S. presidential election to lead to heightened volatility in healthcare stocks.

Biotech sector update: Going for gold
Timely & Topical

Biotech sector update: Going for gold

Amid interest rate cuts and accelerating innovation, the biotechnology sector could be set up for strong performance.

Biotech’s bear market – and early recovery – explained
Timely & Topical

Biotech’s bear market – and early recovery – explained

Low valuations and accelerating innovation are helping biotech recover from one of its worst drawdowns on record.

Hangover cure: Tapping into global growth with thematic equities
Timely & Topical

Hangover cure: Tapping into global growth with thematic equities

Janus Henderson’s recent Global Investment Summit explored growth drivers in equities, noting record levels of innovation in healthcare and technology as well as developments in real estate and sustainability.

Global Life Sciences – strategy update

Global Life Sciences – strategy update

Please watch Andy Acker, Portfolio Manager on the Health Care and Biotech Teams, give an update on the Global Life Sciences strategy, as well as sharing his latest market perspectives and outlook

Identifying AI opportunities in healthcare
Timely & Topical

Identifying AI opportunities in healthcare

Artificial intelligence is only beginning to make inroads into the healthcare sector. Here’s how investors might benefit today.

Why healthcare stocks could catch a break this election year
Timely & Topical

Why healthcare stocks could catch a break this election year

The sector has historically underperformed in the lead-up to U.S. presidential elections, but that may not be the case in 2024.

Global Life Sciences – strategy update

Global Life Sciences – strategy update

Please watch an update on Global Life Sciences strategy from Andy Acker, Portfolio Manager on the Health Care and Biotech Teams, which took place on 22 February 2024.

Global Perspectives: Investing in the small- and midsize healthcare companies innovating for a graying world
Features & Outlooks

Global Perspectives: Investing in the small- and midsize healthcare companies innovating for a graying world

How healthcare’s small- and mid-cap companies could benefit from one of today’s key macroeconomic growth drivers: aging populations.

Healthcare’s small- and mid-cap opportunities amid aging populations
Features & Outlooks

Healthcare’s small- and mid-cap opportunities amid aging populations

With populations in some of the largest economies quickly graying, innovative small- and mid-cap healthcare companies could deliver new growth opportunities for investors.